


GSK963

Cat. No.:	HY-103028A		
CAS No.:	2049868-46-2		
Molecular Formula:	C ₁₄ H ₁₈ N ₂ O		
Molecular Weight:	230.31		
Target:	RIP kinase		
Pathway:	Apoptosis		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 25 mg/mL (108.55 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	4.3420 mL	21.7099 mL	43.4197 mL
		5 mM	0.8684 mL	4.3420 mL	8.6839 mL
		10 mM	0.4342 mL	2.1710 mL	4.3420 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (10.85 mM); Suspended solution; Need ultrasonic Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (10.85 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	GSK963 is a chiral, highly potent and selective inhibitor of RIP1 kinase, with an IC ₅₀ of 29 nM. GSK963 is a selective and potent inhibitor of necroptosis in murine and human cells in vitro ^[1] .
IC₅₀ & Target	IC ₅₀ : 29 nM (RIP1 in FP binding assay) ^[1] .
In Vitro	GSK963 is >10 000-fold selective for RIP1 over 339 other kinases, lacks measurable activity against IDO and has an inactive enantiomer, GSK962, which can be used to confirm on-target effects ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	GSK963 (2 mg/kg) results in a complete protection from TNF+zVAD-induced temperature loss. GSK963 (0.2 mg/kg) also

shows a significant response^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 mice ^[1] .
Dosage:	0.2 mg/kg, 2 mg/kg, 10 mg/kg.
Administration:	IP once.
Result:	Protected mice from TNF+zVAD-induced hypothermia.

CUSTOMER VALIDATION

- Pharmacol Rep. 2023 Jan 31.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Berger SB, et al. Characterization of GSK'963: a structurally distinct, potent and selective inhibitor of RIP1 kinase. Cell Death Discov. 2015 Jul 27;1:15009.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA